

U.S.S.N. 10/737,360  
Office Action Mailed on July 28, 2006  
Amendment Filed January 29, 2007  
Page 2 of 7

RECEIVED  
CENTRAL FAX CENTER

JAN 29 2007

### Listing of the Claims

The current listing of the claims replaces all the prior claims.

1. (Currently amended) A method of treating a proliferative disease in a patient in need of such treatment, said treatment comprising administering, concurrently or sequentially, an effective amount of (1) an anti-platelet agent and (2) an anti-neoplastic agent and/or radiation therapy, wherein the proliferative disease is a solid tumor.
2. (Withdrawn) A method of treating a proliferative disease in a patient in need of such treatment, said treatment comprising administering an effective amount of Plavix or SR 25909.
3. (Withdrawn) A method of inhibiting or preventing proliferative disease in a patient at increased risk by administering an effective amount of an anti-platelet or anti-clotting agent or SR 25909.
4. (Withdrawn) The method of claim 1, further comprising administering a radiosensitizing agent.
5. (Original) The method of claim 1 wherein said anti-platelet agent and antineoplastic agent and/or radiation are administered concurrently.
6. (Cancelled)
7. (Original) The method of claim 1 wherein said anti-platelet agent and antineoplastic agent and/or radiation are administered sequentially.
8. (Original) The method of claim 1 wherein said antineoplastic agent and/or radiation therapy is administered first.
9. (Original) The method of claim 1 wherein said anti-platelet agent is administered first.
10. (Currently amended) The method of claim 1 wherein said proliferative disease solid tumor is glioma.

U.S.S.N. 10/737,360

Office Action Mailed on July 28, 2006

Amendment Filed January 29, 2007

Page 3 of 7

11. (Withdrawn) The method of claim 1 wherein said antineoplastic agent is selected from the group consisting of Uracil mustard, Chlormethine, Clycophosphamide, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Temozolomide, Methotrexate, 5-Fluorouracil, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Gemcitabine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Paclitaxel, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Interferons, Etoposide, Teniposide 17-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Tamoxifen, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estrmustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, Goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, CPT-11, Anastrozole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine.

12. (Original) The method of claim 1 wherein said radiation is ionizing radiation.

13. (Currently amended) The method of claim[[s]] 1[[-3]] wherein the anti-platelet or anti-clotting agent is Plavix clopidogrel bisulfate, [[A]]abciximab, Reopro, [[F]]fondaparinux [[S]]sodium, Arixtra, [[A]]argatroban, Novastan, [[S]]streptokinase, Streptase, [[T]]ticlopidine, Ticlid, [[R]]reteplase, Retavase, [[A]]alteplase, Activase, [[T]]tenecteplase, TNKase, [[E]]eptifibatide, Integrilin, [[T]]tinzaparin, Innohep, [[L]]lepirudin, Refludan, [[D]]dalteparin, Fragmin, [[D]]dipyridamole, Aggrenox, Antithrombin III Human, Thrombate 3, [[A]]anagrelide, Agrylin, [[C]]cilostazol, Pletal, [[T]]tirofiban, Aggrastat, tirofiban hydrochloride, [[P]]pentoxifyline, Trental, [[W]]warfarin, Coumadin, [[D]]danaparoid, Orgaran, [[B]]bivalirudin, Angiomax, [[F]]fondaparinux, Organon, ganirelix acetate, [[A]]ancrod, Viprinex, [[E]]epoprostenol, Flolan, [[C]]cangrelor, or [[X]]ximelagatran.

14. (Currently amended) The method of claim 13 wherein the preferred anti-platelet agent is Plavix clopidogrel bisulfate.

U.S.S.N. 10/737,360  
Office Action Mailed on July 28, 2006  
Amendment Filed January 29, 2007  
Page 4 of 7

15. (Withdrawn)      The method of claim 4 wherein the radiosensitizing agent is Taxotere.
16. (Withdrawn)      A method of treating a proliferative disease in a patient in need of such treatment, said treatment comprising administering, concurrently or sequentially, an effective amount of (1) Plavix and (2) radiation therapy in conjunction with Taxotere.
17. (New)      A method of claim 1, wherein the solid tumor is lung carcinoma.
18. (New)      A method of claim 17, wherein the lung carcinoma is non-small cell lung carcinoma.